1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Acne And Related Disorders - Pipeline Review, H2 2013

Acne And Related Disorders - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 72 pages

Acne And Related Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Acne And Related Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acne And Related Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne And Related Disorders. Acne And Related Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acne And Related Disorders.
- A review of the Acne And Related Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acne And Related Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acne And Related Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acne And Related Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Acne And Related Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acne And Related Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Acne And Related Disorders 9
Acne And Related Disorders Therapeutics under Development by Companies 11
Acne And Related Disorders Therapeutics under Investigation by Universities/Institutes 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Acne And Related Disorders Therapeutics - Products under Development by Companies 17
Acne And Related Disorders Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Acne And Related Disorders Therapeutics Development 19
QLT Inc. 19
Merz GmbH and Co. KGaA 20
Paratek Pharmaceuticals, Inc. 21
Helix BioMedix, Inc. 22
Phynova Group Ltd 23
Syntopix Group Plc 24
Novabiotics Ltd 25
Xenon Pharmaceuticals Inc. 26
NovaLead Pharma Pvt. Ltd. 27
Mimetica Pty Ltd. 28
Fibrocell Sciences, Inc. 29
Acne And Related Disorders - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
HB-1345 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
PYN-6 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
ICX-RHY - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
azficel-T - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Drug For Acne - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
sarecycline hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
DRM-01 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
MTC-896 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
NLP-44 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
HO/04/09 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
FibroStem - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
DS-107-E - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
MUS-92579 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
BBI-3000 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
SYN-0051 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
SYN-0693 + SYN-0117 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
DS-107-F - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
XGP-410 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Anti Acne Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Refaglo - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
XEN-801 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Acne And Related Disorders Therapeutics - Drug Profile Updates 59
Acne And Related Disorders Therapeutics - Dormant Products 62
Acne And Related Disorders - Product Development Milestones 64
Featured News and Press Releases 64
Jul 02, 2013: Fibrocell Science Extends Patent Protection for LAVIV Through 2031 64
Jun 11, 2013: Foamix Successfully Completes Its Minocycline Foam Phase II Clinical Trial 64
May 30, 2013: Novan Announces Promising Results Of SB204 Clinical Study 65
Feb 28, 2013: Novan Therapeutics On Path To Develop First Topical Acne Treatment 65
Sep 10, 2012: Dignity Sciences Receives Notice Of Allowance For US Patent Application Protecting Acne Therapy DS107F 66
May 31, 2012: Photocure Announces Positive Results Of Phase IIb Study Evaluating Visonac In Acne 66
Mar 14, 2012: Combined Therapy Of Acne Medications Offers New Treatment Option For Patients, Henry Ford Hospital Study Reports 67
Mar 12, 2012: Cosmo Announces FDA Acceptance Of Investigational New Drug Application For CB-03-01 68
Mar 11, 2012: Intrepid Announces Development Agreement With Cosmo Pharmaceuticals 68
Nov 03, 2011: Fibrocell Science Announces LAVIV Demonstrates Improvement In Acne Scarring 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72



List of Tables

Number of Products Under Development for Acne And Related Disorders, H2 2013 9
Products under Development for Acne And Related Disorders - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 18
QLT Inc., H2 2013 19
Merz GmbH and Co. KGaA, H2 2013 20
Paratek Pharmaceuticals, Inc., H2 2013 21
Helix BioMedix, Inc., H2 2013 22
Phynova Group Ltd, H2 2013 23
Syntopix Group Plc, H2 2013 24
Novabiotics Ltd, H2 2013 25
Xenon Pharmaceuticals Inc., H2 2013 26
NovaLead Pharma Pvt. Ltd., H2 2013 27
Mimetica Pty Ltd., H2 2013 28
Fibrocell Sciences, Inc., H2 2013 29
Assessment by Monotherapy Products, H2 2013 30
Assessment by Combination Products, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 35
Acne And Related Disorders Therapeutics - Drug Profile Updates 59
Acne And Related Disorders Therapeutics - Dormant Products 62
Acne And Related Disorders Therapeutics - Dormant Products (Contd..1) 63



List of Figures

Number of Products under Development for Acne And Related Disorders, H2 2013 9
Products under Development for Acne And Related Disorders - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Early Clinical Stage Products, H2 2013 15
Discovery and Pre-Clinical Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 30
Assessment by Combination Products, H2 2013 31
Assessment by Route of Administration, H2 2013 32
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Molecule Type, H2 2013 34
Assessment by Stage and Molecule Type, H2 2013 35



Companies Mentioned

QLT Inc.
Merz GmbH and Co. KGaA
Paratek Pharmaceuticals, Inc.
Helix BioMedix, Inc.
Phynova Group Ltd
Syntopix Group Plc
Novabiotics Ltd
Xenon Pharmaceuticals Inc.
NovaLead Pharma Pvt. Ltd.
Mimetica Pty Ltd.
Fibrocell Sciences, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.